# Diabetes Research Hub — Monitor Report

**Run date:** 2026-05-08
**Run type:** Scheduled automated monitor (read-only review)
**Hub root:** `C:\Users\justi\OneDrive\Diabetes_Research`
**Validation level (per Research Doctrine):** BRONZE — automated single-source review; gold-standard claims require expert confirmation

---

## File System Status

| File | Last modified | Age | Status |
|---|---|---|---|
| `Analysis/Results/hub_monitor_report.md` | 2026-05-08 07:05 | fresh | OK |
| `Analysis/Results/clinical_trials_latest.json` | 2026-05-08 07:05 | fresh | OK |
| `Analysis/Results/pubmed_recent_latest.json` | 2026-05-08 07:05 | fresh | OK |
| `Analysis/Results/literature_gap_report.md` | 2026-05-07 08:12 | 1 day | OK |
| `Analysis/Results/literature_gap_data.json` | 2026-04-20 15:35 | 18 days | **STALE — recommend re-run** |
| `Analysis/Results/literature_gap_matrix.xlsx` | 2026-04-20 15:35 | 18 days | **STALE — recommend re-run** |
| `Analysis/Results/literature_gap_report_enriched.md` | 2026-04-03 | 35 days | **STALE — recommend re-run** |

`hub_monitor.py` flagged 540 result files older than 14 days. Most are dated daily snapshots that are correctly archived; only the gap-analysis pipeline outputs (`literature_gap_data.json`, `literature_gap_matrix.xlsx`, `literature_gap_report_enriched.md`) are stale primary deliverables.

Hub inventory: 801 tracked files (561 .json, 98 .md, 72 .html, 60 .py). 3 new files since yesterday, 66 modified, 0 removed.

---

## Clinical Trial Changes

**Snapshot:** 2026-05-08 vs 2026-05-07
- New trials: 0
- Removed trials: 1 — `NCT07163624` (UBT251 Injection Phase II, T2D)
- Status changes: 0
- Newly posted results: 0 (delta vs yesterday)

**7-day delta (vs 2026-05-01):** 11 new trials, dominated by results-posting events for completed implementation/equity studies. New entries of note:

- `NCT07564414` — CagriSema Phase 3 dose-comparison study (Novo Nordisk; NOT_YET_RECRUITING). Adds to CagriSema Phase 3 stack.
- `NCT07563699` — Semaglutide Depot Phase 1/2 (T2D).
- `NCT07564752` — Glycemic-control × HDL composition mechanistic study (RECRUITING).

### Key Phase 3 trials currently RECRUITING (43 total)

Highlights:
- **Vertex VX-880** (`NCT04786262`, `NCT06832410`) — both Phase 3 RECRUITING for islet cell therapy in T1D.
- **Eli Lilly Baricitinib** (`NCT07222137` Stage 3 delay; `NCT07222332` beta-cell preservation) — both Phase 3 RECRUITING.
- **Sanofi Teplizumab** (`NCT07088068`) — Phase 3 RECRUITING.
- **Novo Nordisk Insulin Icodec weekly** (`NCT07076199`) — Phase 3 RECRUITING.
- **vTv Cadisegliatin** (`NCT06334133`) — Phase 3 RECRUITING (glucokinase activator class).

### Recent results posting (last 14 days, 11 trials)

Mostly behavioral/equity-focused completed studies. None are pivotal industry Phase 3 readouts. Notable:
- `NCT05823948` (Novo Nordisk) — Once-weekly insulin Awiqli flash-glucose study, results posted 2026-04-30.
- `NCT05649137` (Novo Nordisk) — Semaglutide for excess weight, results posted 2026-04-27.

### Key-organization activity (55 trials across Vertex, Eli Lilly, Novo Nordisk, Sanofi)

Tracked therapy classes appear well-represented:
- Vertex islet cell therapy: 3 trials (VX-880 Phase 3 ×2, VX-264 Phase 1/2)
- Eli Lilly tirzepatide / baricitinib / orforglipron / retatrutide: 14+ trials
- Novo Nordisk semaglutide / icodec / CagriSema: ~15 trials
- Sana Biotechnology: 0 active trials in current snapshot — may warrant manual check given prior pipeline mentions

---

## PubMed Highlights (lookback 30 days, 147 unique papers)

### Cross-domain papers (10 total — highest-priority items)

These appear in two or more alert domains and warrant manual review:

| PMID | Domains | Title (truncated) |
|---|---|---|
| 42051156 | T1D Immunotherapy + Key Therapy: teplizumab | Considerations for the clinical use of teplizumab in stage 2 T1D — Consensus statement (*Diabetic Medicine*, 2026-04-29) |
| 42092956 | Diabetes AI/ML + Key Therapy: orforglipron | CVOT Summit Report 2025: cardiovascular-kidney-metabolic disease continuum (*Cardiovascular Diabetology*, 2026-05-06) |
| 42097137 | Diabetes Biomarker + Diabetes Drug Repurpose | Multi-cohort proteogenomic analyses reveal genetic effects across the proteome and diseasome (*Cell*, 2026-05-06) |
| 42085931 | Diabetes Microbiome + Diabetes Multi-Omics | Multi-omics analysis of gut microbiome and carotid atherosclerosis in men with T2D (*EBioMedicine*, 2026-05-04) |
| 42078397 | T2D Remission + Diabetes Gene Therapy | A loss-of-function variant in [gene] (*medRxiv*, 2026-04-20) |
| 42089665 | Diabetes Gene Therapy + Diabetes Complications New | VEGFA-Targeted M3-F4 Ionizable Lipid Nanoparticles Improve Diabetic Retinopathy (*Mol. Pharmaceutics*, 2026-05-06) |
| 42070230 | Diabetes Gene Therapy + Diabetes Multi-Omics | Viscous DES-AAV-Foxo1 Delivery System for diabetic wound (*Adv. Science*, 2026-05-03) |
| 42063171 | T2D Remission + Diabetes Complications New | miR-103a-3p in diabetic retinopathy via MFN2 suppression (*Diabetol. Metab. Syndr.*, 2026-04-30) |
| 42046753 | T1D Immunotherapy + Closed Loop AP | Breaking up sitting with active breaks for glucose / vascular health (*BMJ Open Sport Exerc. Med.*, 2026) |
| 42034968 | T1D Stem Cell Cure + T1D Immunotherapy | Bone marrow-derived cells in experimental autoimmune T1D (*BMC Immunology*, 2026-04-25) |

**Top-priority highlights:**
- *Cell* paper (42097137) on proteogenomic effects across the proteome/diseasome directly aligns with our Tier-1 multi-omics biomarker integration program. Worth deep review for biomarker pipeline.
- *Diabetic Medicine* consensus statement on teplizumab clinical use (42051156) is high signal for Stage 2 T1D protocols.
- *Cardiovascular Diabetology* CVOT Summit 2025 review (42092956) summarizes recent CVOT trial landscape.

### Key-therapy mentions in titles/abstracts

- orforglipron: 2 papers (PK bioequivalence; methodological critique of efficacy/safety analyses)
- teplizumab: 3 papers (consensus + 2 real-world Stage 2 T1D studies)
- baricitinib: 1 paper (dermatology case — non-diabetes context)
- zimislecel, retatrutide, CagriSema: 0 PubMed hits in this 30-day window

### Volume trends

- 32 new PubMed papers since 2026-05-07; 29 dropped out of the 30-day window.
- Most domains hit the per-domain query cap (10 papers); domains with low absolute volume in this window: **LADA New Research (2)**, **GLP-1 Pharmacogenomics (1)**, **Diabetes Drug Repurpose (5)**.

---

## Gap Analysis Summary

Source: `literature_gap_report.md` (2026-05-07) and `literature_gap_data.json` (2026-04-20, **stale — 18 days**).

### Top 5 under-researched intersections (ranked, gap-score 100, 0 joint pubs)

1. **Beta Cell Regeneration × Health Equity** — gap_score 100.0; expected 1,615 joint pubs, observed 0. Tier-1 alignment: *high*.
2. **Islet Transplant × Drug Repurposing** — gap_score 100.0; 0 joint pubs. Tier-1 alignment: *high* (matches Drug Repurposing Computational Screening Tier 1, score 18).
3. **Islet Transplant × Health Equity** — gap_score 100.0; 0 joint pubs.
4. **Gene Therapy × LADA** — gap_score 100.0; 0 joint pubs.
5. **Treg / CAR-T × Health Equity** — gap_score 100.0; 0 joint pubs.

Three of the top five gaps fall on the **Health Equity axis**, intersecting therapy classes that may otherwise widen disparities. This is consistent with prior runs and remains the single most actionable cross-cutting theme. **Islet Transplant × Drug Repurposing** is most directly addressable with our existing Tier-1 computational stack (DrugBank + OpenTargets pipelines already validated).

(Validation level: BRONZE — based on keyword-matched PubMed counts, not MeSH; expert confirmation required before publication.)

---

## Breaking News (web check, 7-day window)

Filtered to genuinely significant items only:

- **Sanofi Tzield (teplizumab) sBLA approved** (2026-04-22): FDA expanded indication to children as young as 1 year for delaying onset of Stage 3 T1D. Aligns directly with Eli Lilly baricitinib Phase 3 RECRUITING trials (`NCT07222137`, `NCT07222332`) and Sanofi's own Phase 3 (`NCT07088068`). Worth updating tracker and Stage-2 T1D protocol notes.
- **Novo Nordisk Awiqli (insulin icodec) approved 2026-03-26** for adults with T2D — already reflected in clinical trial snapshot (`NCT05823948` results posted 2026-04-30). Confirms category alignment.
- **MannKind Afrezza pediatric sNDA** — PDUFA 2026-05-29. Watch list item for next monitor run.
- **Boehringer Ingelheim survodutide SYNCHRONIZE-1** Phase 3 obesity readout: 16.6% weight loss vs 3.2% placebo at 76 weeks. Not currently in our therapy-tracking list — consider adding survodutide to alert keywords.
- **Biomea Fusion icovamenib** — Positive 52-week Phase 2 COVALENT-112 in T1D (C-peptide preservation). Not in current trial snapshot keywords; recommend adding.

(Note: web search results contain marketing language; treat efficacy claims as PRELIMINARY until peer-reviewed publication appears in PubMed feed. Validation level: BRONZE.)

---

## Recommended Actions

Ordered by impact:

1. **Re-run gap analysis pipeline** — `python project1_literature_gap_analysis.py`. The underlying `literature_gap_data.json` is 18 days old; with 32 new papers/day, refresh meaningfully changes scores.
2. **Refresh `literature_gap_report_enriched.md`** — 35 days stale; rerun the enrichment step against the new data.
3. **Add survodutide and icovamenib to therapy-alert keywords** — both have material 2026 readouts but are absent from current PubMed and trial monitors. Update `baseline_pubmed_alerts.py` and `baseline_clinical_trials.py` configurations.
4. **Update tracker with Sanofi teplizumab pediatric expansion** (FDA approval 2026-04-22) — affects the Stage-2/Stage-3 T1D row in `Diabetes_Research_Tracker.xlsx`.
5. **Deep-read PMID 42097137** (Multi-cohort proteogenomic analyses, *Cell*, 2026-05-06) — direct Tier-1 multi-omics biomarker integration relevance.
6. **Deep-read PMID 42051156** (teplizumab Stage 2 T1D consensus, *Diabetic Medicine*, 2026-04-29) — protocol-level guidance.
7. **Verify Sana Biotechnology pipeline status** — 0 trials in current snapshot for a tracked org; manual check of company pipeline page recommended in case of NCT IDs not yet captured by query.
8. **Consider gold-standard validation** for the Beta-Cell-Regen × Health-Equity gap: solicit one expert review before any external claim per Research Doctrine.

No file modifications were made by this monitor run.

---

*Generated 2026-05-08 by automated diabetes-hub-monitor scheduled task. All findings are at BRONZE validation level. Cross-reference with domain expert before any external publication or claim.*
